Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study.

Burden of disease Economic modeling Genital herpes Genital ulcer disease HSV-1 HSV-2 Herpes simplex virus Neonatal herpes Probability tree Quality-adjusted life years Sexually transmitted disease

Journal

Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 25 04 2022
revised: 19 10 2022
accepted: 26 12 2022
entrez: 23 3 2023
pubmed: 24 3 2023
medline: 24 3 2023
Statut: epublish

Résumé

Genital herpes (GH), caused by herpes simplex virus type 1 and type 2 (HSV-1, HSV-2), is a common sexually transmitted disease associated with adverse health outcomes. Symptoms associated with GH outbreaks can be reduced by antiviral medications, but the infection is incurable and lifelong. In this study, we estimate the long-term health impacts of GH in the United States using quality-adjusted life years (QALYs) lost. We used probability trees to model the natural history of GH secondary to infection with HSV-1 and HSV-2 among people aged 18-49 years. We modelled the following outcomes to quantify the major causes of health losses following infection: symptomatic herpes outbreaks, psychosocial impacts associated with diagnosis and recurrences, urinary retention caused by sacral radiculitis, aseptic meningitis, Mollaret's meningitis, and neonatal herpes. The model was parameterized based on published literature on the natural history of GH. We summarized losses of health by computing the lifetime number of QALYs lost per genital HSV-1 and HSV-2 infection, and we combined this information with incidence estimates to compute the total lifetime number of QALYs lost due to infections acquired in 2018 in the United States. We estimated 0.05 (95% uncertainty interval (UI) 0.02-0.08) lifetime QALYs lost per incident GH infection acquired in 2018, equivalent to losing 0.05 years or about 18 days of life for one person with perfect health. The average number of QALYs lost per GH infection due to genital HSV-1 and HSV-2 was 0.01 (95% UI 0.01-0.02) and 0.05 (95% UI 0.02-0.09), respectively. The burden of genital HSV-1 is higher among women, while the burden of HSV-2 is higher among men. QALYs lost per neonatal herpes infection was estimated to be 7.93 (95% UI 6.63-9.19). At the population level, the total estimated lifetime QALYs lost as a result of GH infections acquired in 2018 was 33,100 (95% UI 12,600-67,900) due to GH in adults and 3,140 (95% UI 2,260-4,140) due to neonatal herpes. Results were most sensitive to assumptions on the magnitude of the disutility associated with post-diagnosis psychosocial distress and symptomatic recurrences. GH is associated with substantial health losses in the United States. Results from this study can be used to compare the burden of GH to other diseases, and it provides inputs that may be used in studies on the health impact and cost-effectiveness of interventions that aim to reduce the burden of GH. The Center for Disease Control and Prevention.

Sections du résumé

Background UNASSIGNED
Genital herpes (GH), caused by herpes simplex virus type 1 and type 2 (HSV-1, HSV-2), is a common sexually transmitted disease associated with adverse health outcomes. Symptoms associated with GH outbreaks can be reduced by antiviral medications, but the infection is incurable and lifelong. In this study, we estimate the long-term health impacts of GH in the United States using quality-adjusted life years (QALYs) lost.
Methods UNASSIGNED
We used probability trees to model the natural history of GH secondary to infection with HSV-1 and HSV-2 among people aged 18-49 years. We modelled the following outcomes to quantify the major causes of health losses following infection: symptomatic herpes outbreaks, psychosocial impacts associated with diagnosis and recurrences, urinary retention caused by sacral radiculitis, aseptic meningitis, Mollaret's meningitis, and neonatal herpes. The model was parameterized based on published literature on the natural history of GH. We summarized losses of health by computing the lifetime number of QALYs lost per genital HSV-1 and HSV-2 infection, and we combined this information with incidence estimates to compute the total lifetime number of QALYs lost due to infections acquired in 2018 in the United States.
Findings UNASSIGNED
We estimated 0.05 (95% uncertainty interval (UI) 0.02-0.08) lifetime QALYs lost per incident GH infection acquired in 2018, equivalent to losing 0.05 years or about 18 days of life for one person with perfect health. The average number of QALYs lost per GH infection due to genital HSV-1 and HSV-2 was 0.01 (95% UI 0.01-0.02) and 0.05 (95% UI 0.02-0.09), respectively. The burden of genital HSV-1 is higher among women, while the burden of HSV-2 is higher among men. QALYs lost per neonatal herpes infection was estimated to be 7.93 (95% UI 6.63-9.19). At the population level, the total estimated lifetime QALYs lost as a result of GH infections acquired in 2018 was 33,100 (95% UI 12,600-67,900) due to GH in adults and 3,140 (95% UI 2,260-4,140) due to neonatal herpes. Results were most sensitive to assumptions on the magnitude of the disutility associated with post-diagnosis psychosocial distress and symptomatic recurrences.
Interpretation UNASSIGNED
GH is associated with substantial health losses in the United States. Results from this study can be used to compare the burden of GH to other diseases, and it provides inputs that may be used in studies on the health impact and cost-effectiveness of interventions that aim to reduce the burden of GH.
Funding UNASSIGNED
The Center for Disease Control and Prevention.

Identifiants

pubmed: 36950038
doi: 10.1016/j.lana.2023.100427
pii: S2667-193X(23)00001-7
pmc: PMC10025423
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100427

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI153351
Pays : United States

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

MMR reports contract for work on cervical cancer elimination modeling in South Africa, not related to the manuscript, from World Health Organization, travel and lodging support for attending a research project meeting at the World Health Organization headquarters in Geneva, Switzerland, not related to the manuscript, from World Health Organization. YL reports postdoctoral fellowship stipend (2020–2022) from Harvard T. H. Chan School of Public Health, not related to the manuscript. SY reports doctoral stipend from New York University Grossman School of Medicine, not related to the manuscript. All other authors report no potential conflicts.

Références

Sex Transm Dis. 2011 Oct;38(10):949-56
pubmed: 21934571
Sex Transm Dis. 2003 Feb;30(2):174-7
pubmed: 12567178
BMC Med. 2005 Dec 12;3:18
pubmed: 16343341
Ann Intern Med. 1983 Jun;98(6):958-72
pubmed: 6344712
Sex Transm Dis. 2006 Mar;33(3):170-4
pubmed: 16505733
Pediatr Infect Dis J. 2011 Feb;30(2):153-7
pubmed: 20811312
Curr Opin Infect Dis. 2004 Jun;17(3):243-6
pubmed: 15166828
Sex Transm Infect. 2011 Mar;87(2):141-8
pubmed: 21097810
Value Health. 2016 Mar-Apr;19(2):255-66
pubmed: 27021761
Lancet. 1984 Sep 29;2(8405):707-11
pubmed: 6148470
Am J Obstet Gynecol. 2004 Dec;191(6):2074-84
pubmed: 15592294
Obstet Gynecol. 2000 Oct;96(4):511-6
pubmed: 11004350
Obstet Gynecol. 2021 Jan 1;137(1):63-71
pubmed: 33278294
Sex Transm Dis. 2005 Sep;32(9):521-5
pubmed: 16118598
Sex Transm Dis. 2021 Apr 1;48(4):260-265
pubmed: 33492103
Clin Infect Dis. 1998 Mar;26(3):541-53; quiz 554-5
pubmed: 9524821
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
PLoS One. 2015 Jan 21;10(1):e114989
pubmed: 25608026
PLoS One. 2015 Oct 28;10(10):e0140765
pubmed: 26510007
Neurotherapeutics. 2016 Jul;13(3):493-508
pubmed: 27106239
BMJ Glob Health. 2020 Mar 8;5(3):e001875
pubmed: 32201620
Arch Pediatr Adolesc Med. 2008 Jul;162(7):665-74
pubmed: 18606938
Adv Exp Med Biol. 2011;697:221-30
pubmed: 21120729
Scand J Infect Dis Suppl. 1996;100:27-32
pubmed: 9163020
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S759-62
pubmed: 26602614
Clin Infect Dis. 2023 Feb 8;76(3):e810-e819
pubmed: 35684943
Med Decis Making. 2006 Jul-Aug;26(4):410-20
pubmed: 16855129
J Acquir Immune Defic Syndr. 2021 Sep 1;88(1):19-30
pubmed: 34117163
Sex Transm Dis. 2021 Apr 1;48(4):266-272
pubmed: 33492102
Sex Transm Dis. 2021 Aug 1;48(8S):S4-S10
pubmed: 33967231
Am J Obstet Gynecol. 2005 Feb;192(2):483-8
pubmed: 15695991
Arch Neurol. 2008 May;65(5):596-600
pubmed: 18474734
MMWR Recomm Rep. 2021 Jul 23;70(4):1-187
pubmed: 34292926
Vaccine. 2020 Nov 25;38(50):8032-8039
pubmed: 33121846
BMC Med. 2019 Mar 11;17(1):57
pubmed: 30853029
Ann Intern Med. 1994 Dec 1;121(11):847-54
pubmed: 7978697
Am J Manag Care. 1997 Oct;3(10):1551-8
pubmed: 10178461
Clin Dev Immunol. 2013;2013:369172
pubmed: 23606868
Lancet Glob Health. 2017 Mar;5(3):e300-e309
pubmed: 28153513
Health Qual Life Outcomes. 2022 Feb 16;20(1):25
pubmed: 35172828
N Engl J Med. 2000 Mar 23;342(12):844-50
pubmed: 10727588
Bull World Health Organ. 2020 May 01;98(5):315-329
pubmed: 32514197
N Engl J Med. 1991 Feb 14;324(7):444-9
pubmed: 1988829
Natl Vital Stat Rep. 2019 Nov;68(13):1-47
pubmed: 32501202
Sex Transm Infect. 2005 Jun;81(3):267-70
pubmed: 15923300
Pediatrics. 2001 Aug;108(2):230-8
pubmed: 11483782
Prim Care Companion CNS Disord. 2015 Jan 29;17(1):
pubmed: 26137360
Sex Transm Dis. 2002 Oct;29(10):608-22
pubmed: 12370529
Clin Infect Dis. 2013 Feb;56(3):344-51
pubmed: 23087395
Clin Microbiol Rev. 2004 Jan;17(1):1-13
pubmed: 14726453
Lancet Infect Dis. 2017 Dec;17(12):1303-1316
pubmed: 28843576
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):e15-8
pubmed: 24047975
Teratology. 1989 Jan;39(1):1-10
pubmed: 2655150
Obstet Gynecol. 1996 Oct;88(4 Pt 1):603-10
pubmed: 8841227
Open Forum Infect Dis. 2021 Apr 29;8(7):ofab218
pubmed: 34262986
Genitourin Med. 1994 Feb;70(1):40-5
pubmed: 8300099
Lancet Reg Health Am. 2022 Sep 05;16:100364
pubmed: 36777156
AIDS Behav. 2022 Mar;26(3):795-804
pubmed: 34436714
Ann Intern Med. 1999 Jul 6;131(1):14-20
pubmed: 10391810
Natl Vital Stat Rep. 2020 Nov;69(12):1-45
pubmed: 33270553
Am J Obstet Gynecol. 2005 Sep;193(3 Pt 2):1274-9
pubmed: 16157151
Vaccine. 2019 Nov 28;37(50):7336-7345
pubmed: 28647165
Sex Transm Infect. 2011 Oct;87(6):458-63
pubmed: 21636616
N Engl J Med. 2009 Oct 1;361(14):1376-85
pubmed: 19797284

Auteurs

Shiying You (S)

Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.

Reza Yaesoubi (R)

Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.

Kyueun Lee (K)

Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.

Yunfei Li (Y)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Samuel T Eppink (ST)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Katherine K Hsu (KK)

Division of Sexually Transmitted Disease Prevention & HIV/AIDS Surveillance, Massachusetts Department of Public Health, Boston, MA, USA.

Harrell W Chesson (HW)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Thomas L Gift (TL)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Andrés A Berruti (AA)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Joshua A Salomon (JA)

Center for Health Policy / Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA.

Minttu M Rönn (MM)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Classifications MeSH